Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Acumen Pharmaceuticals Inc shares valued at $11,769 were purchased by Doherty James J. on Jan 08 ’26. At $1.82 per share, Doherty James J. acquired 6,467 shares.
Also, Meisner Derek M purchased 36,911 shares, netting a total of over 67,244 in proceeds.
Before that, Barton Russell had added 3,530 shares to its account. In a trade valued at $6,562, the Officer bought Acumen Pharmaceuticals Inc shares for $1.86 each.
As published in their initiating research note from Citigroup on June 17, 2025, Acumen Pharmaceuticals Inc [ABOS] has been a Buy and the price target has been revised to $4. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of December 12, 2023, Deutsche Bank has initiated its “Buy” rating for ABOS.
Analyzing ABOS Stock Performance
On last trading session, Acumen Pharmaceuticals Inc [NASDAQ: ABOS] plunged -6.53% to $1.86. The stock’s lowest price that day was $1.72, but it reached a high of $1.95 in the same session. During the last five days, there has been a drop of approximately -11.85%. Over the course of the year, Acumen Pharmaceuticals Inc shares have jumped approximately 0.54%. Shares of the company reached a 52-week high of $2.1400 on 01/02/26 and a 52-week low of $1.7200 on 01/08/26.
Support And Resistance Levels for Acumen Pharmaceuticals Inc (ABOS)
According to the 24-hour chart, there is a support level at 1.7367, which, if violated, would cause prices to drop to 1.6133. In the upper region, resistance lies at 1.9667. The next price resistance is at 2.0733. RSI (Relative Strength Index) is 42.54 on the 14-day chart, showing neutral technical sentiment.
Is Acumen Pharmaceuticals Inc subject to short interest?
Stocks of Acumen Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.75 million shares to 0.57 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 1.32 million shares. A decline of -131.98% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.71 of the overall float, the days-to-cover ratio (short ratio) decline to 3.71.
Which companies own the most shares of Acumen Pharmaceuticals Inc (ABOS)?
In terms of Acumen Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 251.76% from the previous closing price of $1.99. Analysts anticipate Acumen Pharmaceuticals Inc stock to reach 7 by 2026, with the lowest price target being 7. In spite of this, 5 analysts ranked Acumen Pharmaceuticals Inc stock as Buy at the end of 2026. On May 18, 2023, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $13.
